NO973884L - Aminosyrepreparater og anvendelse derav for klinisk ernæring - Google Patents

Aminosyrepreparater og anvendelse derav for klinisk ernæring

Info

Publication number
NO973884L
NO973884L NO973884A NO973884A NO973884L NO 973884 L NO973884 L NO 973884L NO 973884 A NO973884 A NO 973884A NO 973884 A NO973884 A NO 973884A NO 973884 L NO973884 L NO 973884L
Authority
NO
Norway
Prior art keywords
tnf
amino acid
levels
macrophage
reduction
Prior art date
Application number
NO973884A
Other languages
English (en)
Norwegian (no)
Other versions
NO973884D0 (no
Inventor
Heinz Schneider
Ronald G Thurman
Original Assignee
Novartis Nutrition Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08392694 external-priority patent/US5656608B1/en
Priority claimed from GBGB9512100.0A external-priority patent/GB9512100D0/en
Application filed by Novartis Nutrition Ag filed Critical Novartis Nutrition Ag
Publication of NO973884D0 publication Critical patent/NO973884D0/no
Publication of NO973884L publication Critical patent/NO973884L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pediatric Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO973884A 1995-02-23 1997-08-22 Aminosyrepreparater og anvendelse derav for klinisk ernæring NO973884L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08392694 US5656608B1 (en) 1995-02-23 1995-02-23 Amino acid compositions and methods of treatment using same
GBGB9512100.0A GB9512100D0 (en) 1995-06-14 1995-06-14 Improvements in or relating to organic compounds
PCT/EP1996/000739 WO1996025861A1 (en) 1995-02-23 1996-02-22 Amino acid compositions and use thereof in clinical nutrition

Publications (2)

Publication Number Publication Date
NO973884D0 NO973884D0 (no) 1997-08-22
NO973884L true NO973884L (no) 1997-10-17

Family

ID=26307213

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973884A NO973884L (no) 1995-02-23 1997-08-22 Aminosyrepreparater og anvendelse derav for klinisk ernæring

Country Status (18)

Country Link
EP (1) EP0810829B1 (es)
JP (1) JPH11501301A (es)
KR (1) KR19980702436A (es)
CN (1) CN1175887A (es)
AT (1) ATE191615T1 (es)
AU (1) AU710527B2 (es)
BR (1) BR9607336A (es)
CA (1) CA2210499A1 (es)
CZ (1) CZ266797A3 (es)
DE (1) DE69607750T2 (es)
DK (1) DK0810829T3 (es)
ES (1) ES2145997T3 (es)
FI (1) FI972744L (es)
HU (1) HUP9800049A3 (es)
NO (1) NO973884L (es)
PL (1) PL182205B1 (es)
PT (1) PT810829E (es)
WO (1) WO1996025861A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
CA2260886A1 (en) * 1996-07-30 1998-02-05 Novartis Nutrition Ag Amino acid composition and use thereof in treating tumor growth and metastasis
US6096785A (en) * 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
GB9701674D0 (en) * 1997-01-28 1997-03-19 Novartis Nutrition Ag Use of organic compounds
DE69823739T2 (de) * 1997-06-05 2005-04-28 Novartis Nutrition Ag Glycin zur Vorbeugung oder Behandlung von Transplantatabstossungen
US6310097B1 (en) * 1997-07-28 2001-10-30 Riken Protecting and survival promoting agent for central nervous cell
US6143786A (en) * 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
DE10257360A1 (de) * 2002-12-09 2004-07-08 Fresenius Kabi Deutschland Gmbh Gastro-intestinal verabreichbare Formulierung und deren Verwendung
WO2005023021A1 (ja) 2003-09-02 2005-03-17 Bbk Bio Corporation ダイエット食品
EP1591118A1 (en) 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Use of melatonin in preventing postoperative complications
KR100555904B1 (ko) * 2004-05-19 2006-03-03 주식회사 오스코텍 큰느타리버섯과 오가피의 혼합 생약재 추출물 및 이를유효성분으로 하는 골다공증 예방 및 치료용 조성물
US20100215631A1 (en) * 2006-06-14 2010-08-26 Anita Hartog Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof
AU2008347177B2 (en) 2008-01-04 2014-04-17 Société des Produits Nestlé S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US20100179089A1 (en) * 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
EP2440200B8 (en) * 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
KR101213825B1 (ko) * 2010-07-16 2012-12-18 서울대학교산학협력단 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물
EA030970B8 (ru) 2010-09-24 2019-01-31 Юниверсити Оф Флорида Рисёч Фаундейшн, Инк. Композиция для восстановления функции тонкого кишечника, способы ее приготовления и применения
EP4417256A3 (en) 2013-03-11 2024-10-23 University of Florida Research Foundation, Inc. Materials and methods for improving lung function
CN107106527B (zh) 2014-11-24 2020-11-24 恩特林斯科健康解决方案股份公司 用于治疗疾病症状的氨基酸组合物
EP3355878B1 (en) * 2015-10-02 2024-09-25 N.V. Nutricia Glycine for use in tolerance induction in allergic patients
FR3041882B1 (fr) * 2015-10-06 2019-04-12 Universite D'angers Preparation pharmaceutique pour le traitement preventif de lesions d'ischenie reperfusion
CA3135553C (en) 2016-10-04 2024-05-21 University Of Florida Research Foundation, Incorporated Amino acid compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591893B1 (fr) * 1985-12-19 1988-11-10 Centre Nat Rech Scient Compositions nutritionnelles carencees en methionine destinees a inhiber le developpement et la dissemination des tumeurs malignes chez les mammiferes
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
ATE174794T1 (de) * 1991-09-27 1999-01-15 Univ Texas Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease

Also Published As

Publication number Publication date
KR19980702436A (ko) 1998-07-15
DK0810829T3 (da) 2000-08-28
FI972744A0 (fi) 1997-06-25
MX9706140A (es) 1997-11-29
BR9607336A (pt) 1997-11-25
HUP9800049A2 (hu) 1998-05-28
NO973884D0 (no) 1997-08-22
HUP9800049A3 (en) 1999-01-28
DE69607750T2 (de) 2000-08-31
FI972744A7 (fi) 1997-08-22
CN1175887A (zh) 1998-03-11
PL321238A1 (en) 1997-11-24
AU4879596A (en) 1996-09-11
FI972744L (fi) 1997-08-22
WO1996025861A1 (en) 1996-08-29
CA2210499A1 (en) 1996-08-29
AU710527B2 (en) 1999-09-23
ATE191615T1 (de) 2000-04-15
EP0810829A1 (en) 1997-12-10
CZ266797A3 (cs) 1998-03-18
ES2145997T3 (es) 2000-07-16
JPH11501301A (ja) 1999-02-02
PL182205B1 (pl) 2001-11-30
EP0810829B1 (en) 2000-04-12
DE69607750D1 (de) 2000-05-18
PT810829E (pt) 2000-08-31

Similar Documents

Publication Publication Date Title
FI972744A0 (fi) Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa
Lips et al. Determinants of vitamin D status in patients with hip fracture and in elderly control subjects
Schjoldager et al. Oxyntomodulin from distal gut: role in regulation of gastric and pancreatic functions
BOIVIN et al. Effect of a purified amylase inhibitor on carbohydrate metabolism after a mixed meal in healthy humans
CA2410880A1 (en) 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
CA2229279A1 (en) Nutritional and/or dietary composition and method of using the same
NZ272610A (en) The manufacture of dispersible tablets containing fluoxetine by direct compression
Pusztai et al. Lipid accumulation in obese Zucker rats is reduced by inclusion of raw kidney bean (Phaseolus vulgaris) in the diet
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
JP2001524119A (ja) 増加した骨吸収の治療のための植物抽出物
EP1263448B1 (en) Maca and antler for augmenting testosterone levels
EP0981352B8 (en) Use of aplidine for the treatment of cardiovascular diseases
CN109862906A (zh) 用于口服的活性剂的制剂
NO994431L (no) Ny formulering
McLaren Nutrition and wound healing
MXPA02012064A (es) Complejos de farmaco macromoleculares y composiciones que los contienen.
JPH0667832B2 (ja) 腫瘍性疾患の治療に用いるプログルミド含有医薬組成物
Bloomgarden International Diabetes Federation Meeting, 1997: Type 2 diabetes: its prevalence, causes, and treatment
Wildburger et al. Comparison of the values of basic fibroblast growth factor determined by an immunoassay in the sera of patients with traumatic brain injury and enhanced osteogenesis and the effects of the same sera on the fibroblast growth in vitro
Konturek et al. Effect of thyrotropin-releasing hormone on gastro-intestinal secretions in dogs
Vidon et al. Does lansoprazole influence postprandial digestive function?
HU194736B (en) Improved process for production of antiinflammable preparative
D’Souza et al. Calcium metabolism in pancreatic disease
Wang et al. Effects of arginine-devoid diets in chronically uremic rats
Spannagel et al. Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application